Exploring the anti-inflammatory effects of curcumin encapsulated within ferritin nanocages: a comprehensive in vivo and in vitro study in Alzheimer's disease.

Autor: Morasso C; Istituti Clinici Scientifici Maugeri IRCCS, Pavia, 27100, Italy., Truffi M; Istituti Clinici Scientifici Maugeri IRCCS, Pavia, 27100, Italy., Tinelli V; Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, Milano, 20126, Italy., Stivaktakis P; Department of Toxicology & Forensic Sciences, Faculty Medicine, University of Crete, Heraklion, Greece., Di Gerlando R; Department of Biology and Biotechnology 'L. Spallanzani' , University of Pavia, Pavia, Italy.; IRCCS Mondino Foundation, Pavia, 27100, Italy., Francesca D; IRCCS Mondino Foundation, Pavia, 27100, Italy., Perini G; IRCCS Mondino Foundation, Pavia, 27100, Italy., Faisal M; Department of Pharmacology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia., Aid J; Department of Pharmacology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia., Noridov B; Department of Pharmacology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia., Lee B; Department of Pharmacology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia., Barbieri L; Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, Milano, 20126, Italy., Negri S; Istituti Clinici Scientifici Maugeri IRCCS, Pavia, 27100, Italy., Nikitovic D; Department of Histology-Embryology, School of Medicine, University of Crete, Heraklion, 71003, Greece., Thrapsanioti LN; Department of Histology-Embryology, School of Medicine, University of Crete, Heraklion, 71003, Greece., Tsatsakis A; Department of Toxicology & Forensic Sciences, Faculty Medicine, University of Crete, Heraklion, Greece., Cereda C; Department of Biomedical and Clinical Sciences, Università di Milano, Milan, 20157, Italy.; Center of Functional Genomics and Rare diseases, Department of Pediatrics, Buzzi Children's Hospital, Milan, 20154, Italy., Bonizzi A; Istituti Clinici Scientifici Maugeri IRCCS, Pavia, 27100, Italy.; Department of Biomedical and Clinical Sciences, Università di Milano, Milan, 20157, Italy., Mazzucchelli S; Department of Biomedical and Clinical Sciences, Università di Milano, Milan, 20157, Italy., Prosperi D; Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, Milano, 20126, Italy., Hickey MA; Department of Pharmacology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia. miriam.ann.hickey@ut.ee., Corsi F; Istituti Clinici Scientifici Maugeri IRCCS, Pavia, 27100, Italy. fabio.corsi@icsmaugeri.it.; Department of Biomedical and Clinical Sciences, Università di Milano, Milan, 20157, Italy. fabio.corsi@icsmaugeri.it., Gagliardi S; IRCCS Mondino Foundation, Pavia, 27100, Italy.
Jazyk: angličtina
Zdroj: Journal of nanobiotechnology [J Nanobiotechnology] 2024 Nov 17; Vol. 22 (1), pp. 718. Date of Electronic Publication: 2024 Nov 17.
DOI: 10.1186/s12951-024-02897-4
Abstrakt: Background: The global demographic shift towards an aging population is generating a rise in neurodegenerative conditions, with Alzheimer's disease (AD) as the most prominent problem. In this landscape, the use of natural supplements has garnered attention for their potential in dementia prevention. Curcumin (Cur), derived from Curcuma longa, has demonstrated promising pharmacological effects against AD by reducing the levels of inflammatory mediators. However, its clinical efficacy is hindered by poor solubility and bioavailability. Our study introduces the use of H-Ferritin nanocages (HFn) as a nanoformulation vehicle for Cur, aiming to enhance its therapeutic potential for AD. In this work, we characterized a nanoformulation of Cur in HFn (HFn-CUR) by evaluating its safety, stability, and its transport across the blood-brain barrier (BBB) in vitro. Moreover, we evaluated the efficacy of HFn-CUR by transcriptomic analysis of peripheral blood mononuclear cells (PBMCs) from both AD patients and healthy controls (HC), and by using the well-established 5xFAD mouse model of AD.
Results: Our data show that HFn-CUR exhibits improved water dispersibility, is non-toxic, and can traverse the BBB. Regarding its activity on PBMCs from AD patients, HFn-CUR enhances cellular responses to inflammation and reduces RAGE-mediated stress. Studies on an AD mouse model demonstrate that HFn-CUR exhibits mild beneficial effects on cognitive performance. Moreover, it effectively reduces microgliosis and astrogliosis and in vivo in mouse, suggesting potential neuroprotective benefits.
Conclusions: Our data suggest that HFn-CUR is safe and effective in reducing inflammation in both in vitro and in vivo models of AD, supporting the need for further experiments to define its optimal use.
Competing Interests: Declarations Ethics approval and consent to participate All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the Helsinki declaration and its later amendments or comparable ethical standards. The study design was examined by the IRBs of the enrolling institutions. The study protocol to obtain blood from patients was approved by the Ethical Committee of the IRCCS Mondino Foundation (Pavia, Italy) (Code: 20170001758). Informed consent was obtained from all subjects involved in the study. Consent for publication Not applicable. Competing interests The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje